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Background: We aimed at assessing the factors that can influence results of the dissemination of an already validated,
new generation commercial Point-of-Care Test (POCT) for detecting celiac disease (CD), in the Mediterranean area,
when used in settings where it was designed to be administered, especially in countries with poor resources.
Methods: Pragmatic study design. Family pediatricians at their offices in Italy, nurses and pediatricians in Slovenia and
Turkey at pediatricians’, schools and university primary care centers looked for CD in 3,559 (1-14 yrs), 1,480 (14-23 yrs)
and 771 (1-18 yrs) asymptomatic subjects, respectively. A new generation POCT detecting IgA-tissue antitransglutaminase
antibodies and IgA deficiency in a finger-tip blood drop was used. Subjects who tested positive and those suspected of
having CD were referred to a Celiac Centre to undergo further investigations in order to confirm CD diagnosis. POCT
Positive Predictive Value (PPV) at tertiary care (with Negative Predictive Value) and in primary care settings, and POCT
and CD rates per thousand in primary care were estimated.
Results: At tertiary care setting, PPV of the POCT and 95% CI were 89.5 (81.3-94.3) and 90 (56-98.5) with Negative
Predictive Value 98.5 (94.2-99.6) and 98.7% (92-99.8) in children and adults, respectively. In primary care settings of
different countries where POCT was performed by a different number of personnel, PPV ranged from 16 to 33%
and the CD and POCT rates per thousand ranged from 4.77 to 1.3 and from 31.18 to 2.59, respectively.
Conclusions: Interpretation of POCT results by different personnel may influence the performance of POC but
dissemination of POCT is an urgent priority to be implemented among people of countries with limited resources, such
as rural populations and school children.
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Celiac Disease (CD) is a systemic immune-mediated dis-
order triggered by dietary gluten in genetically susceptible
persons and is characterized by a broad range of clinical
presentations and variable damage to the small-intestinal
mucosa [1].
The active disease is characterized by gluten-dependent
auto-antibodies against endomysium and, more precisely,
protein type 2 (‘tissue’) transglutaminase, the celiac* Correspondence: magazzug@unime.it
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nectin [2,3].
Detection of these auto-antibodies in serum represents a
valuable tool for identifying new celiac patients presenting
with only mild gastro-intestinal symptoms, non-specific
general complaints or extra-intestinal manifestations, or
for screening asymptomatic subjects [4,5]. The prevalence
of CD in various populations is around 1% [6-8].
The burden of unrecognized CD in the Mediterranean
area has been estimated in terms of morbidity costs and
mortality [9]. The projected number of CD diagnoses in
2020 is 5 million cases (1 million celiac children), with a
relative increase of 11% compared to 2010. The estimatedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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during the delay between symptom onset and diagnosis
(mean - 6 years for adults, 2 years for children) will be
about €4 billion (€387 million for children) over the next
10 years. A delay in diagnosis is expected to increase mor-
bidity, in terms of nutritional deficiencies and, especially,
of gluten related autoimmune diseases and mortality:
about 600,000 celiac patients will die in the next 10 years,
with an excess of 44.4% versus age- and sex-matched con-
trols. In order to face this non-communicable epidemic, it
is necessary to have accurate tests available.
IgA anti tissue transglutaminase antibodies (IgA-tTG)
from commercial enzyme-linked immunosorbent assays
(ELISA) utilized for CD testing require a serum sample,
need equipped laboratories and are too expensive for coun-
tries with poor resources, such as most of those in the
Mediterranean area, where patients and families are not
able to reach referral centers or centralized laboratories
located far away.
Due to the necessity of drawing blood in a CD screening
study, 30% of parents of children initially selected refused
blood sampling [10].
There is thus the need for quick, easy-to-perform, low-
cost and widely accessible celiac antibody tests which can
be carried out at the Point-of-Care (POC) in countries
with poor resources.
For this reason, a rapid test for detecting CD was de-
veloped more than 20 years ago [11].
Since this first home-made assay, which was not applied
in clinical practice, several articles have recently been pub-
lished on new commercial rapid tests [12-31], regarding
also an assay which detects anti-deamidated gliadin pep-
tides [31].
Among these, a POC test (POCT) has already been vali-
dated, mostly in tertiary centers [13,15-18,20,22,23,26,27]
and in primary care settings [14,19,21,24,25]. However,
both the first [14,19,21] and the new generation [24,25]
POCT have been administered by personnel, generally one
person, dedicated to performing the test [14,24] or by
the same researchers [21,25]. The exception is a study
performed in Hungary where 120 district nurses screened
6-year old children for CD with a first generation POCT
and demonstrated 100% specificity, but a lower sensi-
tivity of the test [19]. Therefore, it is important to as-
sess if a test conceived for point-of-care utilization can
maintain its accuracy in settings where it will be
disseminated.
The Medicel network (www.medicel.unina.it/) is a pro-
ject supported by the Italian Ministry of Health, Direc-
tion of International Affairs and comprises 16 countries
with different resources and facilities (and limitations) for
diagnosing CD [32], ranging from those that have tertiary
level CD centers and family doctors to those in which,
apart from lack of facilities and personnel, there areeconomic restraints for referring patients suspected of
having celiac disease to Health Centers.
We aimed at assessing the factors that can influence
results of the dissemination of an already validated new
generation commercial POCT for detecting CD, in the
Mediterranean area, when it is used in the settings where
it was designed to be administered.
Methods
We adopted a pragmatic design in which potential bias
has been assessed. Awareness of the potential biases and
its implications allows us to discuss possible solutions
and overcome such bias.
Celiac centers from three countries, Italy, Slovenia and
Turkey, participated in the study. Ethical institutional re-
view boards at each collection site approved the study in
the 3 centers participating in the study: in Italy, at the
University Hospital, Messina; in Slovenia at the University
Medical Centre Ljubljanska, Maribor; in Turkey, at the
Faculty of Medicine, Ankara University, Ankara. Written
informed consent for participation in the study was
obtained from participants or, where participants were
children, a parent or guardian.
In Table 1, demographic data of enrolled subjects and
information on setting and personnel performing the test
in the various countries participating in the study are
shown.
The “new generation” Biocard™ celiac test (AniBiotech®,
Vantaa, Finland), based on an immunochromatographic
technique, was used. This technique detects IgA-tTG in
whole blood. The procedure was performed as previously
described [16]: with a drop of whole blood taken by finger
prick, with bands visually detected after 5 minutes but no
later than 10 minutes as recommended by the manufac-
turer’s instructions.
Moreover, the “new generation” rapid test contains a
second line (control line) with an antihuman IgA antibody.
The test result is positive if both lines are seen, negative if
only the control line forms. In the case of IgA deficiency,
no line is visible on the test.
In Italy, the study involved 39 family pediatricians in
Sicily. At their offices, all consecutive asymptomatic chil-
dren were offered the POCT and those who tested posi-
tive or were found to be IgA negative on Biocard testing
were referred to a Celiac Center (Group A in Table 1).
Moreover, all consecutive children (Group B) and adults
(Group C) referred for symptoms suggestive of CD by
other physicians, or because they were first degree rela-
tives of celiac patients, were enrolled at the referral Centre
where they underwent both POCT, performed by a
biologist or a physician, and conventional celiac serology
determination.
In Slovenia, participants spontaneously underwent POCT
from 6 secondary schools and 1 Medical Faculty after
Table 1 Setting of the study, personnel performing the test and demographic data of enrolled subjects
Country Italy Slovenia Turkey
Setting A) Primary care: Family
pediatrician’s office
D) Primary care – screening of secondary school
students – mostly in rural area of NE Slovenia
Primary care: Pediatrician’s office
B) Celiac centre
pediatric patients
E) Students from Medical Faculty and Faculty of
Health Sciences University of Maribor -
screening
C) Celiac centre adult
patients
Personnel
performing
POCT
A) Family
pediatricians
D) Trained nurse, student and pediatrician,
pediatric gastroenterologist – as supervisor
Nurse and pediatrician
B) Physician and
biologist
E) Trained nurse, trained students, pediatric
gastroenterologist – as supervisor
C) Physician and
biologist
No. subjects tested
(age range)
A) 3,559 (1-14 yrs)
asymptomatic children
A) 1,000 (14-18y) secondary school students 771 (1-18 years) asymptomatic children at school
(666) and at a primary care pediatrician’s office (105)
B) 206 (1-18 yrs) children
for suspected CD
B) 480 (18-23y) University students
C) 85 (>18 yrs) adults for
suspected CD
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one trained nurse and 2 trained students with a pediatric
Gastroenterologist as supervisor. Subjects who tested posi-
tive or with no line were sent to the Referral Celiac Center
to undergo conventional celiac serology.
In Turkey, asymptomatic children at school and at a
primary care pediatrician’s office underwent POCT per-
formed by trained pediatricians and nurses. All children
who tested positive or were found to be IgA negative on
Biocard testing were referred to a tertiary level center to
undergo celiac conventional serology.
In all the Centers, conventional IgA-tTG assays were
performed with one of the kits recommended by ESP-
GHAN [33].
Subjects who had positive serology underwent upper
gastrointestinal endoscopy with duodenal biopsies. Hist-
ology was classified according to the Marsh criteria modi-
fied by Oberhuber [34]. All patients definitively diagnosed
as having celiac disease were consequently given a gluten-
free diet.Table 2 Diagnostic accuracy of POCT at the Italian Celiac Cen
Subjects No.
Tested
No. positive No. negative Sensitivity
%(No.CD found) (No.CD found)
Paediatric 206 76 130 97.1
(68) (2) (93.1-100)
Adult 85 10 75 90.0
(9) (1) (70.4-100)
(95% CI).
PPV: Positive Predictive Value.
NPV: Negative Predictive Value.
LR: Likelihood ratio.Sensitivity, specificity, Positive and Negative Predictive
Value (PPV and NPV, respectively) and positive and
negative likelihood ratio were calculated for POCT per-
formed in patients referred to the Celiac Center in Italy.
Intestinal biopsy was performed in all subjects in whom
one of the tests, including POCT, was positive at the
Center, and Marsh type 2 (in children) or 3 at histology
was considered the gold standard of CD diagnosis.
Positive Predictive Value of POCT and rate per thou-
sand positive POCT and CD were calculated for subjects
in whom POCT was performed by different persons in
other settings. In these cases, intestinal biopsy was per-
formed if one of the conventional celiac serology tests was
positive and histology was considered the gold standard.
False positive POCTs were considered subjects with
normal conventional celiac serology, as, in these asymp-
tomatic children, performing intestinal biopsy was judged
unethical.
At tertiary centers, laboratory personnel were blinded to
POCT results while assaying celiac conventional serology.tre
Specificity
%
PPV % NPV % LR + LR -
94.1 89.5 98.5 16.5 0.03
(90.1-98.1) (81.3-94.3) (94.2-99.6) (8.4-32.39) (0.01-0.12)
98.7 90.0 98.7 67.5 0.10
(96.1-100) (56.0-98.5) (92.0-99.8) (9.5-478) (0.02-0.65)
Table 3 Rate of positive Point-of-care Test and Celiac disease found according to personnel performing the test
Rate per thousand
Country Persons (and No.) performing test Subjects tested POCT + (PPV) CD POCT + CD
ITALY Family (39) pediatricians 3559 111 (16%) 17 31.18 4.77
SLOVENIA Nurse (1) 1480 18 (33%) 7 12.16 4.72
Student (2)
Pediatrician (1)
TURKEY Pediatrician (2) Nurse (1) 771 2* (N.A.) 1 2.59 1.30
*1 patient was not referred to Center to undergo conventional serology and histology and thus PPV was Not Available (NA).
CD: Celiac Disease.
POCT: Point-of-Care Test.
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In Table 2, the performance of POCT at the Italian Celiac
Center is shown.
In Table 3, POC PPV and rates per thousand for POCT
and CD are shown.
The lowest PPV was found in Italy and Slovenia but in
these countries POCT yielded a high rate of positive
cases and of CD.
All false positive cases of POCT (84%) performed by
pediatricians in primary care in Italy were negative at the
POCT performed at the Center by a well experienced39 
Pediatricians
83 (2.3%) 
refused 
3642 PoCT 
offered 
Referred to Center 
3559 PoCT 
performed 
45 No line 111 positive
1 IgG-tTG 
positive 
1 confirmed 
CD
1 IgA-tTG 
positive 
1 confirmed 
CD
9 IgA 
deficiency 
36 normal 
IgA 
8
n
Figure 1 Results in primary care in Italy. Abbreviations: PoCT= Point-of-biologist or physician. In Slovenia, there were 67% false
positive cases while it was not possible to estimate the
number in Turkey as, out of 2 children with positive
POCT, one refused referral to the Celiac Center.
Diagrams of results obtained in Italy, Slovenia and
Turkey are shown in Figures 1, 2 and 3, respectively.
In Italy (Figure 1), out of 45 cases who had no line visible
on the test, 37 had normal IgA at the Center. In one of
these, IgA-tTG was high and histology confirmed CD. In
another case with confirmed IgA deficiency, IgG-tTG was
high and histology confirmed CD. Out of 20 children with 
3403 negative  
20 tTG 
positive 
9 tTG 
egative 
Stop 
17 confirmed 
CD 
2 refused 
Care Test; tTG = anti-tissue transglutaminase antibodies.
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tTG (<4 X upper limit of normal) and absent antiendomy-
sial antibodies. Following requests by the families, the chil-
dren have not yet undergone duodenal biopsy and are in
follow up with a gluten containing diet. The lowest ELISA
value among the 17 children with POCT positive in whom
CD diagnosis was confirmed was about four fold the cut-
off.
The refusal rate of parents to allow their children to
undergo POCT in the pediatrician’s office was 2.3%.
In Slovenia (Figure 2) the refusal rate was not estimable
due to the spontaneous participation of subjects after pub-
lic invitation.
In Turkey (Figure 3) the refusal rate was 1.7%. One
family refused duodenal biopsy in one out of the 2 chil-
dren who resulted tTG positive and, therefore, it was not
possible to estimate CD rate per thousand (Table 3).
Discussion
Our pragmatic study was aimed at getting information
to then disseminate a well validated, cheap and rapid test
for CD that does not require an equipped laboratory,
above all in some Mediterranean countries where most
of the patients do not have enough resources to reach a
referral centre.
The ideal test should be cheap and feasible, with very
high sensitivity and specificity.1 Pediatrician 1
2 Studen
Refusal rate 
Not applicable 
PoCT
pubbl
Referred to Center 
1480 PoCT perform
who accepted i
6 No line 18 positi
6 IgA 
deficiency 
6 normal      
IgG tTG 
Figure 2 Results in primary care in Slovenia. Abbreviations: PoCT= PoinConsidering that the POCT used in our study has pre-
viously been validated, and that its high diagnostic ac-
curacy has been confirmed in the present study at the
tertiary level center in Italy, variations in PPV of the new
generation POCT do not depend on the test but rather,
apart from the prevalence of higher CD in tertiary care
centers than in community settings, on the operator and
interpretation of test. It is of interest that in our study,
the lowest PPV was obtained in settings where the POCT
was performed by more than one operator, such as pri-
mary care pediatricians in their office or personnel who
are not completely dedicated to performing diagnostic
procedures. In Slovenia, where all the POCTs were super-
vised by a skilled pediatric gastroenterologist with long ex-
perience with these tests, a lower level of false positive was
obtained in comparison with that observed among pri-
mary care pediatricians. In a screening study performed in
Tunisia, using the same new generation POCT [25], the
interpretation of faint test lines explained different PPVs
obtained. Moreover, in a previous study performed in
Hungary by 120 non-trained district nurses [19], in which
each one performed a median of 18 first generation POC
tests, specificity was 100% but sensitivity of the test was
low. These results may be due, as the authors suggested,
to the lower sensitivity obtained on site by the nurses
interpreting faint test lines as negative results. In our
study, differences between positive tests and faint test Nurse 
ts  
 offered by 
ic invitation 
ed on subjects 
nvitation 
1456 negative ve 
7 tTG 
positive 
7 tTG 
negative 
Stop 
7 confirmed 
CD 
4 refused 
t-of-Care Test; tTG = anti-tissue transglutaminase antibodies.
2 Pediatricians 
1 Nurse 
14 (1.7 %) 
refused 
785 PoCT 
offered  
Referred to Center 
771 PoCT 
performed 
766 negative 3 No line 2 positive 
1 IgG-tTG 
negative 
2 IgA-tTG 
negative  
1 IgA 
deficiency 
 1 tTG 
positive 
2 normal 
IgA 
Stop 
1 confirmed 
CD 
1 refused 
Figure 3 Results in primary care in Turkey. Abbreviations: PoCT= Point-of-Care Test; tTG = anti-tissue transglutaminase antibodies.
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that personnel in primary care also referred subjects to the
Center with faint test lines who afterwards tested negative
at conventional serology, as shown in a previous study
[25]. On the other hand, it was reported that doubtful re-
sults with faint lines of positivity have actually been ob-
served at the end of the reading time recommended by
the manufacturer (9–10 minutes). Further investigation by
serology revealed that all of these “doubtful” results were
false positive [25]. Unfortunately, we did not record the
test reading exact time and participants were asked to
read the test within 10 minutes as recommended by the
manufacturer.
In countries with poor resources, it would be advisable
for this POCT to be performed by a minimum number of
trained people, in order to minimize costs induced by false
positive cases.
Two previously published studies which were performed
in two centers (Greece and Tunisia) from countries par-
ticipating in the Medicel network, using the same POCT,
obtained the highest PPV (100%) [24,25].
In Greece [24], properly trained nonmedical staff per-
formed the POCT on toddlers attending nursing school.In Tunisia [25], screening for CD by POCT was per-
formed by a team of 3 doctors and a nurse previously
trained in reading the test. Among the children who
tested negative with POCT, a small sample consisting
of the first 54 were called in for conventional testing in
order to assess NPV of the test. NPV, although estimated
in a small sample, was 100%.
In the present study, NPV of POCT was assessed in a
tertiary level Centre in a population with high and mod-
erate prevalence of CD, such as that represented by pa-
tients referred with the suspicion of CD and first degree
relatives, respectively. POCT at the tertiary centre, and
in a population with the above cited prevalence of CD,
had a very high NPV but this must be assessed in set-
tings other than a Celiac centre and in populations with
low prevalence of CD. NPV was previously reported lower
in a study performed in Libyan children who participated
in a screening study but the results were based on a first
generation POCT [21]. However, while waiting for further
studies aimed at assessing NPV by assaying conventional
CD serology in patients with negative POCT, we believe
that it is cost-effective to start huge case finding and,
above all, screening strategies [35,36] based on POCT
Costa et al. BMC Gastroenterology  (2014) 14:219 Page 7 of 8in order to face the epidemic of CD and decrease morbid-
ity, mortality and costs in the Mediterranean area [9,32].
These costs, even in the worst possible scenario, allow us
to save money due to the excessive costs of patients with
undiagnosed CD, keeping in mind that the so-called active
case-finding may fail to identify the majority of them
[35,36].
Conclusions
Our study suggests that factors that can influence the re-
sults of a POCT dissemination in the Mediterranean area,
apart from the prevalence of CD in different settings
where it is applied, include interpretation of results by ap-
propriately trained personnel performing the test. More
studies are needed to decide the correct time limit for test
and interpretation of faint lines.
We believe that the populations amongst which the
dissemination of POCT would be of the greatest benefit
and where it is most "urgent" to implement are in countries
with limited resources, above all rural populations where
most of the people are not able to reach the referral
centres.
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